Nerandomilast in Idiopathic Inflammatory Myopathy-Associated Interstitial Lung Disease: Subgroup Analysis of the Phase III FIBRONEER™-ILD Trial (ACR Convergence 2026) - Sep 8, 2026 - Abstract #2914; Pres time: Nov 10, 2026; 03:45 PM - 04:00 PM; Location: W311A-D; In Person; "PPF was defined using INBUILD criteria.2 Concomitant nintedanib was permitted if the dose was stable...†Use of cyclophosphamide, tocilizumab, mycophenolate (in the prior 8 weeks), or rituximab (in the prior 6 months) was not permitted at screening but could be initiated after 6 months of the trial to manage worsening of systemic disease. ‡Treatment with prednisone >15 mg/day or equivalent (in the prior 4 weeks) was not permitted at screening but could be initiated after 6 months of the trial to manage worsening of systemic disease... In this exploratory subgroup analysis of the FIBRONEER™-ILD trial, nerandomilast showed consistent trends toward reduced FVC decline and disease progression in patients with IIM-ILD. These findings, despite the small sample size, suggest that nerandomilast may have therapeutic potential in IIM-ILD. References 1."
P3 data • Idiopathic Pulmonary Fibrosis • Infectious Disease • Interstitial Lung Disease • Myositis • Pneumonia • Pulmonary Disease • Respiratory Diseases
|
|
Rohit Aggarwal1; Hui Gu2; Zhiguang Huo2; Brian Jonat2; Kremena Simitchieva2; Eric White2; Gerrit Weimann3; Shervin Assassi4
|